The Inflation Reduction Act in numbers: impact on the development of small molecule medicines

Further research into the effect of the Inflation Reduction Act (IRA) on US health care, this time by Partnership for Health Analytic Research (PHAR), has found there could be a significant impact on post-approval research and development of small molecule medicines.  As previously covered on The Evidence Base, various analyses are emerging that model the potential impacts that implementation of the IRA-mandated Medicare drug pricing policies could have on US health care. Only last week, Vital Transformation released two reports showing the negative effects on US Food and Drug Administration (FDA) approvals, drug discovery and employment in the US. Now...